Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 896467, 9 pages
http://dx.doi.org/10.1155/2013/896467
Research Article

The Effects of Xuefu Zhuyu and Shengmai on the Evolution of Syndromes and Inflammatory Markers in Patients with Unstable Angina Pectoris after Percutaneous Coronary Intervention: A Randomised Controlled Clinical Trial

1Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Xuan Wu, Beijing 100053, China
2Beijing Hospital of Traditional Chinese Medicine, Dong Cheng, Beijing 100010, China
3Beijing University of Chinese Medicine, Chao Yang, Beijing 100029, China
4The Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Dong Cheng, Beijing 100700, China
5Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Hai Dian, Beijing 100700, China

Received 11 January 2013; Revised 8 March 2013; Accepted 3 April 2013

Academic Editor: Alan Bensoussan

Copyright © 2013 Jie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Yangfeng, “Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades,” Chinese Journal of Cardiology, vol. 29, no. 2, pp. 74–79, 2001. View at Google Scholar
  2. W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. D. Grech, “ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure,” British Medical Journal, vol. 326, no. 7399, pp. 1137–1140, 2003. View at Google Scholar · View at Scopus
  4. X. Ma, T. Wu, M. P. Robich et al., “Drug-eluting stents,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 3, pp. 192–201, ,2010. View at Google Scholar
  5. S. Aziz, J. L. Morris, and R. A. Perry, “Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation,” Journal of Invasive Cardiology, vol. 19, no. 4, pp. E96–E98, 2007. View at Google Scholar · View at Scopus
  6. H. L. Kim, K. W. Park, J. J. Kwak et al., “Stent-related cardiac events after non-cardiac surgery: drug-eluting stent versus bare metal stent,” International Journal of Cardiology, vol. 123, no. 3, pp. 353–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Camenzind, “Treatment of in-stent restenosis—back to the future?” New England Journal of Medicine, vol. 355, no. 20, pp. 2149–2151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. Pfisterer, B. Richartz, and S. Silber, “The BASKET-LATE study: basel stent cost-effectiveness trial—late thrombotic events trial,” Herz, vol. 31, no. 3, p. 259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Ten Berg, H. W. Thijs Plokker, and F. W. A. Verheugt, “Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention,” Current Controlled Trials in Cardiovascular Medicine, vol. 2, no. 3, pp. 129–140, 2001. View at Google Scholar · View at Scopus
  10. C. Keji and X. Hao, “The integration of traditional Chinese medicine and Western medicine,” European Review, vol. 11, no. 2, pp. 225–235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. B. J. Chen, Z. Q. Pan, and X. X. Su, “Study on changes of TCM syndrome in patients with coronary heart disease before and after intervention treatment,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 27, no. 8, pp. 689–691, 2007. View at Google Scholar · View at Scopus
  12. G. L. Zheng and S. H. Wang, “Clinical effect and mechanismn of xuefu zhuyu capsule in treating unstable angina pectoris,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 29, no. 1, pp. 65–68, 2009. View at Google Scholar · View at Scopus
  13. X. Y. Wang and Y. Lou, “Combination of XuefuZhuyu decoction with western medicine for unstable angina in 56 cases with coronary heart disease,” Tianjin Journal of Traditional Chinese Medicine, vol. 26, no. 6, p. 521, 2009. View at Google Scholar
  14. F. S. Cai, “Observation on clinical therapeutic effect of Xuefuzhuyu Capsules in treating angina pectoris,” Journal of Liaoning University of Traditional Chinese Medicine, vol. 11, no. 8, pp. 128–129, 2009. View at Google Scholar
  15. Y. R. Li, H. F. Zhang, J. Du, and D. W. SU, “Clinical observation of XuefuZhuyu Capsule for unstable angina in patients with coronary heart disease,” Journal of Liaoning University of Traditional Chinese Medicine, vol. 10, no. 11, pp. 103–104, 2008. View at Google Scholar
  16. J. Song, W. Y. Chen, L. Y. Wu et al., “A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu Decoction on endothelial cells,” Chinese Journal of Integrative Medicine, vol. 18, no. 7, pp. 502–506, 2012. View at Google Scholar
  17. Q. Y. Zhang, Q. L. Wang, J. F. Su et al., “Angiogenesis effects of Xuefu Zhuyu Decoction and VEGF protein expression of rats with acute myocardial Ischemia,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 18, no. 2, pp. 53–54, 2011. View at Google Scholar
  18. E. Braunwald, E. M. Antman, J. W. Beasley et al., “ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina),” Circulation, vol. 102, no. 10, pp. 1193–1209, 2000. View at Google Scholar
  19. Specialty Committee of Activating Blood and Removing Stasis CAOIM, “Diagnostic standard of blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 7, no. 3, 1987. View at Google Scholar
  20. Z. Shen and W. Wang, “Standards reference of TCM deficiency syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 1986, no. 10, p. 598, 1986. View at Google Scholar
  21. M. Z. Zhang and L. Wang, “The academic ideology of DENG TieTao treatment of sydroms after PCI based on syndrome differentiation,” Journal of Traditional Chinese Medicine, vol. 14, no. 1, pp. 32–33, 2006. View at Google Scholar
  22. G. R. Shroff, Y. Y. Cen, D. A. Duprez, and B. A. Bart, “Relationship between carotid artery stiffness index, BNP and high-sensitivity CRP,” Journal of Human Hypertension, vol. 23, no. 12, pp. 783–787, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. N. S. Rost, P. A. Wolf, C. S. Kase et al., “Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study,” Stroke, vol. 32, no. 11, pp. 2575–2579, 2001. View at Google Scholar · View at Scopus
  24. W. Koenig, M. Sund, M. Fröhlich et al., “C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992,” Circulation, vol. 99, no. 2, pp. 237–242, 1999. View at Google Scholar · View at Scopus
  25. S. Verma, C. H. Wang, S. H. Li et al., “A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis,” Circulation, vol. 106, no. 8, pp. 913–919, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Falk, P. K. Shah, and V. Fuster, “Coronary plaque disruption,” Circulation, vol. 92, no. 3, pp. 657–671, 1995. View at Google Scholar · View at Scopus
  27. A. M. Zeiher, H. Goebel, V. Schachinger, and C. Ihling, “Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina,” Circulation, vol. 91, no. 4, pp. 941–947, 1995. View at Google Scholar · View at Scopus
  28. X. Zhang, F. Zhao, C. Xu et al., “Circadian rhythm disorder of thrombosis and thrombolysis-related gene expression in apolipoprotein E knock-out mice,” International Journal of Molecular Medicine, vol. 22, no. 2, pp. 149–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Katayama, K. Yano, H. Nakashima et al., “Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty,” Circulation Journal, vol. 69, no. 6, pp. 654–658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. K. Yip, C. J. Wu, H. W. Chang et al., “Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty,” Chest, vol. 127, no. 5, pp. 1491–1497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Pasterkamp, A. H. Schoneveld, D. J. Hijnen et al., “Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery,” Atherosclerosis, vol. 150, no. 2, pp. 245–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. D. L. Brown, M. S. Hibbs, M. Kearney, C. Loushin, and J. M. Isner, “Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina,” Circulation, vol. 91, no. 8, pp. 2125–2131, 1995. View at Google Scholar · View at Scopus
  33. P. Sarén, H. G. Welgus, and P. T. Kovanen, “TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages,” Journal of Immunology, vol. 157, no. 9, pp. 4159–4165, 1996. View at Google Scholar · View at Scopus
  34. S. H. Kim, Y. J. Kang, W. J. Kim et al., “TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages,” Circulation Journal, vol. 68, no. 4, pp. 396–399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Kai, H. Ikeda, H. Yasukawa et al., “Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes,” Journal of the American College of Cardiology, vol. 32, no. 2, pp. 368–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Kalela, T. A. Koivu, T. Sisto et al., “Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 62, no. 5, pp. 337–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Blankenberg, H. J. Rupprecht, O. Poirier et al., “Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease,” Circulation, vol. 107, no. 12, pp. 1579–1585, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Inokubo, H. Hanada, H. Ishizaka, T. Fukushi, T. Kamada, and K. Okumura, “Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome,” American Heart Journal, vol. 141, no. 2, pp. 211–217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Funayama, S. E. Ishikawa, N. Kubo et al., “Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction,” Circulation Journal, vol. 68, no. 5, pp. 451–454, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. F. B. Aksungar, A. E. Topkaya, and M. Akyildiz, “Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting,” Annals of Nutrition and Metabolism, vol. 51, no. 1, pp. 88–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. L. M. Graham, L. E. Daly, H. M. Refsum et al., “Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project,” Journal of the American Medical Association, vol. 277, no. 22, pp. 1775–1781, 1997. View at Google Scholar · View at Scopus